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Background and Aims: Although most ovarian cancers express estrogen (ER), progesterone (PR), and
androgen (AR) receptors, they are currently not applied in clinical decision making. We explored the prognostic
impact of sex steroid hormone receptor protein and mRNA expression on survival in epithelial ovarian cancer.
Methods: Immunohistochemical stainings for ERα, ERβ, PR, and AR were assessed in relation to survival in 118
serous and endometrioid ovarian cancers. Expression of the genes encoding the four receptors was studied in
relation to prognosis in the molecular subtypes of ovarian cancer in an independent data set, hypothesizing that
the expression levels and prognostic impact may differ between the subtypes. Results: Expression of PR or AR
protein was associated with improved 5-year progression-free (P = .001 for both) and overall survival (P b .001 for
both, log-rank test). ERα and ERβ did not provide prognostic information. Patients whose tumors coexpressed PR
and AR had the most favorable prognosis, and this effect was retained in multivariable analyses. Analyses of the
corresponding genes using an independent data set revealed differences among the molecular subtypes, but no
clear relationship between high coexpression of PGR and AR and prognosis. Conclusions: A favorable outcome
was seen for patients whose tumors coexpressed PR and AR. Gene expression data suggested variable effects in
the different molecular subtypes. These findings demonstrate a prognostic role for PR and AR in ovarian cancer
and support that tumors should be stratified based on molecular as well as histological subtypes in future studies
investigating the role of endocrine treatment in ovarian cancer.
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Epithelial ovarian cancer accounts for about 3% of female cancers and
is the leading cause of death from gynecologic malignancy. Although
a somewhat decreased incidence and slightly improved survival have
been noted during the last decades, the majority of tumors are
diagnosed at advanced stages and the relative 5-year survival is less
than 50% [1]. New treatment concepts have shown promising results
in clinical trials, but predictive markers are needed for refined
therapeutic strategies and will likely need to be stratified in relation to
histopathological and molecular subtypes of ovarian cancer [2,3].
Endocrine factors play key roles in ovarian cancer development,
with risk reduction related tomultiparity and use of oral contraceptives
[4,5]. Likewise, estrogen (ER), progesterone (PR), and androgen (AR)
receptors represent prognostic markers and therapeutic targets in, e.g.,
breast cancer and prostate cancer [6–8]. Estrogen regulates growth and
differentiation in the normal ovaries and has been demonstrated to
have mutagenic effects. Progesterone, on the other hand, induces
apoptosis and decreases cell membrane permeability, leading to
decreased invasive potential. Progesterone may however stimulate
growth at low concentrations, whereas higher concentrations seem to
have growth inhibitory effects [9,10]. The majority of ovarian cancer
cases are diagnosed in perimenopausal and postmenopausal women
[1]. After menopause, when the estradiol level decreases, androgens are
still produced and also seem to influence ovarian cancer development.
Androgens promote cell proliferation, and androgen levels are
decreased by the use of oral contraceptives [11]. Although the
majority of ovarian cancers express ER, antiestrogen treatment has not
been successful in ovarian cancer. Several studies have assessed the
prognostic value of endocrine receptor expression in ovarian cancer,
concluding that expression of PR is prognostically favorable, whereas
the results on ERα and ERβ are contradictory. Likewise, the
association with other clinical risk factors is variable [12–17]. A
review andmeta-analysis by Zhao et al. including in total 35 studies, of
which 23 considered the prognostic value of ER, did not find any
evidence of an effect of ER on prognosis [18]. Recently though, a
multinational study including almost 3000 women with invasive
epithelial ovarian cancer showed that ER expression was associated
with improved disease-specific survival in endometrioid tumors,
whereas PR expression was prognostic in serous tumors [19].
Furthermore, AR expression has been suggested to be associated
with a favorable prognosis in serous ovarian tumors and is
hypothesized to predict response to antiandrogen treatment [20,21].
Overall, the frequency of ER, PR, and AR expression seems to decrease
with increasing malignant potential in ovarian tumors, but
reports regarding covariation of the receptors are contradictory
[12,16,20,22,23]. In general, however, studies of endocrine respon-
siveness in ovarian cancer are limited by the relatively small number of
cases in each study and have not yet led to clinical application.
Ovarian cancer is a highly heterogeneous disease, and increasing
evidence suggests that the different subtypes respond differently to
targeted treatments and also that prognostic and predictive
biomarkers may be subtype specific. In addition to the histopatho-
logical classification of ovarian cancers, gene expression profiling has
revealed intrinsic molecular subtypes with additional prognostic
information [24–26]. Apart from outlining the prognostic value of
ER (both the α and β isoforms), PR, and AR in serous and
endometrioid ovarian cancer, we aimed to explore the potential
additional effect of coexpression of two or more of these receptors.
We also sought to compare the immunohistochemical findings withthe mRNA levels of the genes encoding each receptor in relation to
the previously published molecular subtypes of ovarian cancer, using
an independent data set and hypothesizing that the expression and
prognostic impact of the genes encoding the sex hormone receptors
may vary between the molecular subtypes. To the best of our
knowledge, no reports so far have stratified for molecular subtype in
relation to endocrine receptor expression in ovarian cancer, either on
the mRNA or on the protein level, and this approach has the potential




One hundred eighteen patients with epithelial serous (n = 87) and
endometrioid (n = 31) ovarian cancer were included in the present
study. The patients were recruited from a consecutive cohort study in
the southern Swedish health care region between June 1998 and June
2000 (n = 128 patients with ovarian cancer, outlined in Malander
et al. [27]) and at the oncogenetic counseling at Lund University
Hospital from 1981 to 1997 (n = 18 patients). The small number of
patients recruited via oncogenetic counseling reflects the limited
extent of counseling service at that time. Of the 146 eligible patients,
4 patients with clear cell tumors and 10 patients with mucinous
tumors were excluded because these tumors are generally not expected
to express sex steroid hormone receptors [10,13]. Another 14 patients
with tumors of unknown primary, mixed histologies, or undifferen-
tiated carcinomas were excluded to reduce external factors, which may
potentially bias the analyses. Of the 118 included patients, 30 (25%)
had a verified BRCA1 (n = 26) or BRCA2 (n = 4) mutation. Detailed
clinical features of included tumors are outlined in Supplementary
Table S1. Tumor samples were collected at primary surgery, and the
patients had not received chemotherapy before this. Information on
amount of residual disease after surgery was not available.
Fifty-nine of 118 (50%) patients received postoperative carbopla-
tin (AUC5) and paclitaxel (175 mg/m2) treatment, 18/118 (15%)
received carboplatin (AUC5) and cyclophosphamide (500 mg/m2),
and 17/118 (14%) with varying disease stages were reported not
to have received any postoperative chemotherapy. Information on
chemotherapy treatment was missing for 24/118 (21%) patients,
whereas no information on hormonal treatment was available.
Eleven of 30 (37%) of the patients with BRCA mutations were
also diagnosed with breast cancer either before or after the
ovarian cancer diagnosis. All deaths within the follow-up time,
however, were related to ovarian cancer. Histopathological
subtypes were reviewed by a gynecological pathologist (A. M.).
The histologic subtype and grade were determined according to
Silverberg and WHO 2003, and hematoxylin and eosin–stained
slides were used to assess tumor grade [28,29]. All tumors were
staged according to the International Federation of Gynecology
and Obstetrics criteria [30]. Ethical approval for the study was
granted by the Lund University ethics committee (Sweden), and
all patients had given their written informed consent to
participate in the study.
Immunohistochemical Stainings
Existing tissue micro array (TMA) blocks were used for evaluation
of protein expression by immunohistochemical staining of ERα,
ERβ, PR, and AR. The construction of the TMA blocks is outlined in
Figure 1. Examples of immunohistochemical stainings for ERα, ERβ, PR, and AR. Top row from left to right: positive
immunohistochemical stainings (≥10% stained cells) for ERα, ERβ, PR, and AR. Bottom row from left to right: negative
immunohistochemical stainings (b10% stained cells) for ERα, ERβ, PR, and AR. Magnification, 40×.
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DAKO A/S, Glostrup, Denmark, clone 1D5, cat. #M7047, dilution
1:100; ERβ, DAKO, M7292, dilution 1:10; AR, DAKO, M3562,
dilution 1:100) and one rabbit polyclonal antibody (PR, DAKO, cat.
#A0098, dilution 1:50) were used. For ERα and PR stainings, antigen
retrieval was achieved by microwave treatment in 10 mM citrate buffer
(pH 6.0, 15 minutes). Antigen retrieval for ERβ and AR stainings was
achieved using a pressure cooker and DAKO’s solutions (ERβ pH 6, cat.
#S1699, AR pH 9, cat. #S2367), following the manufacturer’s
instructions (DAKO). All immunohistochemical stainings were per-
formed using an automated immunostainer (Techmate 500, DAKO),
following the manufacturer’s instructions, with application of the
Envision systems for visualization (DAKO). Breast cancer tissue known
to be positive for the respective receptors was used as positive controls, and
ovarian cancer tissue with removal of the primary antibodies was used as
negative controls. The ERα and PR nuclear stainings were evaluated
independently by authors S. M. and M. N. and ERβ and AR by J. M. J.
and N. A. At least three cores per tumor (diameter 0.6 mm) were used to
determine the staining pattern. In general, antibodies showed homog-
enous staining across cores within individual tumors (N80%), but in cases
where heterogeneous staining was observed, the staining pattern
representing the majority of the tumor cells was used. Stainings
were evaluated regarding percent tumor cells with stained nuclei and
staining intensity, where 1 = weak, 2 = moderate, and 3 = strong
staining intensity. In line with the Swedish national guidelines for
breast cancer, 10% stained tumor cells was used as cutoff for positive
versus negative stainings [31]. Thus, for statistical comparisons,
only the prevalence of stained tumor cells was taken into account,
and b10% stained tumor cells were dichotomized as 0 and ≥10%
stained tumor cells as 1. Examples of positive and negative nuclear
stainings for the respective receptors are shown in Figure 1. Positive
versus negative stainings were studied in relation to 5-year
progression-free survival (PFS) and overall survival (OS).Sex Steroid Hormone Receptor Gene Expression in Relation to
Molecular Subtype
To expand the hypothesis, we aimed to outline if the association
between a favorable prognosis and receptor expression at the protein
level could be detected on the mRNA level. For this purpose, an
independent, publicly available data set consisting of 285 high-grade
serous and endometrioid, borderline as well as low-grade serous and
endometrioid ovarian tumors, fallopian tube, and primary peritoneal
cancers was used for studying the expression of the ESR1, ESR2, PGR,
and AR genes, coding for ERα, ERβ, PR, and AR, respectively [24].
Gene probes specific for ESR1, ESR2, PGR, and ARwere identified and
aligned with the reference genome assembly human build 19
(GRCh37/hg19, released February 2009) using the online BLAST-Like
Alignment Tool, identifying DNA sequences with ≥95% similarity of
≥25 bases. When multiple probe sets identified the same gene, the
probe set with the highest number of probes identifying the specific
gene was chosen and used for further analyses. The data set was
originally used for transcriptional subtyping of ovarian cancers,
revealing six different subtypes (C1-C6) of which the four subtypes
representing high-grade serous ovarian cancer are now commonly
termed “mesenchymal” (C1), “immunoreactive” (C2), “differentiated”
(C4), and “proliferative” (C5) [25,26]. C3 represents borderline and a
few serous tumors of varying differentiation grade, and C6 represents
low-grade endometrioid tumors [24]. High versus low expression of the
respective genes was studied in relation to PFS and OS in the different
molecular subtypes using the median mRNA expression level across all
the samples as cutoff. Because of limited follow-up time in this data set,
5-year PFS and OS were not evaluable in all subtypes, and therefore
3-year PFS and OS were used as end points.
Statistical Analyses
The prognostic value of immunohistochemical expression of ERα,
ERβ, PR, and AR was investigated using PFS time and OS time, both
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interval between date of diagnosis and the first sign of disease recurrence
(clinical and/or radiological) or death of any cause, whichever came first.
OS time was defined as the time interval between date of diagnosis and
death of any cause, obtained frommedical records and the Swedish civil
registration register. No patients were lost to follow-up before 5 years,
and all patients who died before 5 years of diagnosis died of ovarian
cancer, i.e., had persistent or recurrent disease. In the publicly available
gene expression data set, high versus low expression of ESR1, ESR2,
PGR, and AR in the respective molecular ovarian cancer subtypes, using
the median as cutoff, was investigated using PFS time and OS time as
end points, here censored at 3 years because of limited follow-up time
[24]. PFS time andOS time were defined asmentioned above. For PFS,
disease progression or death of any cause was considered an event, and
patients lost to follow-up were censored at the time of last notification.
For OS, deaths within 3 years were considered as events, and patients
lost to follow-up were censored at the time of last notification. Of the
patients who died before 3 years of diagnosis, all but two died of ovarian
cancer. OS and PFS were for both data sets estimated using the
Kaplan-Meier method and compared between groups using the
log-rank test. For protein expression, hazard ratios (HRs) with 95%
confidence intervals (95% CIs) were calculated in univariable and
multivariable analyses using Cox proportional hazards regression,
adjusted for clinical factors known to influence ovarian cancer survival
(stage, age at diagnosis, histological grade, histology, and BRCA
mutation status) [32–34]. A previous Gynecologic Oncology Group
study has shown an association between increasing age at diagnosis and
tumor progression or death, with the greatest risk among patients
≥70 years at diagnosis [32]. This cutoff was therefore used in the
present study. Stage (III-IV vs I-II), age at diagnosis (b70 vs ≥70 years),
histology (serous versus endometrioid), and BRCA mutation status
(BRCA mutation versus wild type) were treated as binary factors and
histological grade as a categorical factor on three levels with grade 3 as
reference. Chemotherapy was not adjusted for in the multivariable
analyses because treatment data were missing for 21% of the patients,
and all patients reported to have received chemotherapy were given
platinum-containing combinations. Instead, a stability analysis, i.e., a
separate multivariable analysis including the variable postoperative
chemotherapy (platinum-containing chemotherapy versus no treat-
ment), was performed for 5-year PFS and OS. To account for
histology-dependent differences in receptor expression, which may not
be captured by adjusting for histology in the multivariable analysis due
to the uneven histological distribution, the independent effect of the
receptors on survival was also assessed in serous and endometrioid
tumors separately. In the external data set, comparisons between
mRNA levels in the different molecular subtypes were performed using
Kruskal-Wallis test. Associations between receptor protein expression
and clinical parameters were assessed using Fisher exact test, except for
the ordinal variables stage and grade where the Mann-Whitney test was
used. Statistical analyses of protein expression data were performed in
SPSS statistics version 22, and analyses on gene expression data were
performed in R version 3.1.0. All P values were two-sided.Results
Expression of Sex Steroid Hormone Receptors and Relation
to Outcome
The expression and the prognostic value were first assessed
individually for each marker, with ERα positivity detected in 52/118(44%), ERβ positivity in 102/117 (82%), PR positivity in 36/118
(31%), and AR positivity in 52/118 (44%) tumors (Supplementary
Table S1, Figure 1). The representation of stage, grade, age at
diagnosis, histology, BRCA mutation status, and postoperative
chemotherapy in relation to receptor status is outlined in Table 1.
PR negativity was associated with both advanced stage and advanced
grade (P = .006 and P = .001, respectively), and AR negativity was
associated with high grade (P = .025) and older age at diagnosis
(≥70 years, P = .017). ERβ positivity was associated with high grade
(P = .016, Table 1). No evidence of associations between ERα and
stage, grade, or age at diagnosis was found. Likewise, no associations
between protein expression of any of the receptors and histological
subtype or BRCA mutation status were observed. Expression of either
PR or AR alone was associated with improved 5-year PFS and OS
(PFS, HR 0.42 [0.24-0.71], P = .001 and OS, HR 0.34 [0.19-0.62],
P b .001 for PR+ versus PR−; PFS, HR 0.48 [0.30-0.75], P = .001
and OS, HR 0.38 [0.23-0.63], P b .001 for AR+ versus AR−,
respectively; Table 2). In contrast, ERα or ERβ as single markers
influenced neither the 5-year PFS nor the OS (PFS, HR 1.2
[0.77-1.8], P = .4 and OS, HR 1.1 [0.69-1.7], P = .7 for
ERα + versus ERα−; PFS, HR 1.2 [0.62-2.2], P = .6 and OS, HR
1.2 [0.60-2.3], P = .6 for ERβ + versus ERβ−, respectively; Table 2;
Supplementary Figures S1-2). The effect of combined expression of
the receptors on survival was then explored. Both PR positivity and
AR positivity signified an improved 5-year PFS and OS irrespective of
ERα or ERβ status (data not shown). Patients with PR-positive
tumors had a median 5-year PFS of N60 months and patients with
AR-positive tumors had a median PFS of 42 months compared with
20 and 18 months, respectively, for patients whose tumors were PR-
or AR-negative. The median 5-year OS for patients with both
PR-positive and AR-positive tumors was N60 months compared with
40 and 37 months, respectively, for PR- or AR-negative cases
(Figures 2 and 3). The survival curves for patients with discordant
(i.e., PR+/AR− or PR−/AR+) or absent (i.e., PR−/AR−) protein
expression of PR and AR were almost identical and, when combined,
showed a 5-year median PFS of 21 months and median OS of
41 months compared with N60-month median PFS and OS for
patients whose tumors were double positive for PR and AR (Figure 4).
Because ERα and ERβ expression did not influence survival, they
were excluded from the multivariable analyses. The favorable
prognosis seen among patients with PR+/AR+ tumors compared
with patients whose tumors had discordant or absent PR and AR
expression remained after adjustment for stage, grade, age at
diagnosis, BRCA mutation status, and histology (PFS, HR 0.32
[0.13-0.79], P = .014; OS, HR 0.24 [0.080-0.70], P = .009;
Table 3). The additional effect of coexpression of PR and AR was
evident after adjustment for the same clinical factors as mentioned
above (PFS, P for interaction = .004; OS, P for interaction = .016,
data not shown).
Stability analyses including postoperative chemotherapy for 5-year
PFS and OS did not affect the independent effect of coexpression of
PR and AR, but the evidence of such an effect was weaker (PFS, HR
0.40 [0.15-1.0], P = .064, n = 84 patients [61 events]; OS, HR 0.32
[0.10-1.0], P = .050, n = 84 patients [57 events]; data not shown).
Analyses without the chemotherapy treatment variable were therefore
consistently used throughout this study. The favorable prognosis of
PR+/AR+ tumors also remained when assessed in serous and
endometrioid tumors separately, although the evidence of such an
effect was weaker (OS, HR 0.32 [0.081-1.2], P = .097, n = 73
Table 1. Clinical Characteristics of Patients Included in the Study and Stratified for Hormone Receptor Expression Status
PR AR ERα ERβ ‡ Total
+ − + − + − + −
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
36 82 P † 52 66 P 52 66 P 102 15 P 118
5-Year OS
Events/person years 13/148 62/269 22/209 53/209 34/181 41/237 65/352 10/61 75/418
5-Year OS (%) 63.9 24.4 57.7 19.7 34.6 37.9 36.3 33.3 36.4
5-Year PFS
Events/person years 17/124 67/196 29/170 55/150 39/134 45/187 73/270 11/46 84/320
5-Year PFS (%) 52.8 18.3 44.2 16.7 25.0 31.8 28.4 26.7 28.8
Histology
Serous 23 (64) 64 (78) .12 39 (75) 48 (73) .8 40 (77) 47 (71) .5 78 (76) 9 (60) .2 87 (74)
Endometrioid 13 (36) 18 (22) 13 (25) 18 (27) 12 (23) 19 (29) 24 (23) 6 (40) 31 (26)
Stage
I 10 (28) 5 (6) .006 11 (21) 4 (6) .090 5 (10) 10 (15) .6 12 (12) 2 (13) .18 15 (13)
II 5 (14) 11 (13) 5 (10) 11 (17) 6 (11) 10 (15) 11 (11) 5 (33) 16 (14)
III 18 (50) 52 (63) 31 (60) 39 (59) 35 (67) 35 (53) 64 (63) 6 (40) 70 (59)
IV 3 (8) 14 (17) 5 (10) 12 (18) 6 (11) 11 (17) 15 (15) 2 (13) 17 (14)
Grade
1 12(33) 5 (6) .001 13 (25) 4 (6) .025 9 (17) 8 (12) .6 13 (13) 3 (20) .016 17 (14)
2 8 (22) 16 (19) 10 (19) 14 (21) 10 (19) 14 (21) 18 (18) 6 (40) 24 (20)
3 13 (36) 47 (57) 23 (44) 37 (56) 26 (50) 34 (51) 57 (56) 3 (20) 60 (51)
Missing 3 (8) 14 (17) 6 (11) 11 (17) 7 (13) 10 (15) 14 (14) 3 (20) 17 (14)
Age at diagnosis
Median (years) 56 59.5 55.5 63 60 56 58 63 58
Range (years) 40-78 26-83 26-79 41-83 43-83 26-80 26-83 41-80 26-83
≥70 years 7 (19) 22 (27) .5 7 (13) 22 (33) .017 16 (31) 13 (20) .2 25 (24) 4 (27) 1.0 29 (25)
b70 years 29 (81) 60 (73) 45 (86) 44 (67) 36 (69) 53 (80) 77 (75) 11 (73) 89 (75)
BRCA mutation
BRCA1 6 (17) 20 (24) .4 14 (27) 12 (18) .5 12 (23) 14 (21) .8 24 (23) 2 (13) .12 26 (22)
BRCA2 2 (6) 2 (2) 1 (2) 3 (4) 1 (2) 3 (4) 2 (2) 2 (13) 4 (3)
Wild type 28 (78) 60 (73) 37 (71) 51 (77) 39 (75) 49 (74) 76 (74) 11 (73) 88 (75)
Postoperative chemotherapy
Carboplatin/paclitaxel 15 (42) 44 (54) .2 24 (46) 35 (53) .4 29 (56) 30 (45) .15 51 (50) 8 (53) .2 59 (50)
Carboplatin/cyclophosphamide 8 (22) 10 (12) 8 (15) 10 (15) 9 (17) 9 (14) 18 (18) 0 (0) 18 (15)
No chemotherapy 7 (19) 10 (12) 10 (19) 7 (11) 4 (8) 13 (20) 16 (16) 1 (7) 17 (14)
Missing 6 (17) 18 (22) 10 (19) 14 (21) 10 (19) 14 (21) 17 (17) 6 (40) 24 (20)
* Survival analyses are performed using the Kaplan-Meier method.
† P values are calculated using Fisher exact test, except for the ordinal variables stage and grade where the Mann-Whitney test is used.
‡ ERβ expression is missing for one endometrioid sample.
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P = .073, n = 28 patients [15 events] for endometrioid tumors;
data not shown). Analyses including all tumors and adjusted for
histology were therefore consistently used throughout this study.
Receptor Encoding Genes and Correlations with Molecular
Subtypes
Next, the mRNA levels of ESR1, ESR2, PGR, and AR were
explored in relation to the molecular (transcriptionally defined)
subtypes of ovarian cancer, i.e., “mesenchymal” (C1), “immunore-
active” (C2), “borderline” (C3), “differentiated” (C4), “proliferative”
(C5), and “low-grade endometrioid” (C6). PGR was upregulated in
the subtypes consisting of borderline (C3) and low-grade endome-
trioid tumors (C6) (P b .001). The same tendency was seen for ESR2
(P b .001). Slightly higher median levels of ESR1 were observed in
the immunoreactive (C2), differentiated (C4), and low-grade
endometrioid (C6) subtypes (P b .001), whereas AR levels were
more similar across subtypes (P = .057; Supplementary Figure S3).
Expression of the individual genes in the whole cohort did not predict
OS or PFS, but stratification for molecular subtype revealed a
tendency toward an association between high levels of PGR and
improved 3-year OS in the immunoreactive subtype (C2) (OS, HR
0.33 [0.084-1.3], P = .11; data not shown). Interestingly, despiteprotein expression of ERα not influencing survival in our in-house
TMA cohort, weak evidence of an association between high levels of
ESR1 and both improved 3-year PFS and OS in the proliferative (C5)
subtype was seen (PFS, HR 0.45 [0.19-1.0], P = .058; OS, HR 0.19
[0.041-0.89], P = .035; data not shown). In contrast, low levels of
PGR appeared to be associated with improved 3-year OS in this
subtype, although the evidence of such an effect was very weak (OS,
HR 3.0 [0.80-11.5], P = .10; data not shown). Finally, weak
evidence of an effect of combined high expression of PGR and AR
was seen for 3-year PFS, but not OS, in the immunoreactive subtype
(C2) (PFS, HR 0.43 [0.17-1.0], P = .063; Figure 5).
Discussion
The prognostic value of sex steroid hormone receptor expression in
ovarian cancer is not fully defined. In this study, we can however
demonstrate that expression of PR and AR predicts 5-year PFS and
OS, which is in line with two previous publications [19,20].
Furthermore, coexpression of PR and AR revealed an even better
5-year PFS and OS, and the independent effect of such an interaction
remained after adjustment for known prognostic factors such as stage,
grade, age at diagnosis, histology, and BRCA mutation status in
multivariable analyses. Data on amount of residual disease after
surgery, which is a very strong prognostic factor for ovarian cancer
Table 2
5-Year PFS Univariable Cox 5-Year OS Univariable Cox
n (Events) HR 95% CI P n (Events) HR 95% CI P
PR
(+ vs −) 118 (84) 0.42 0.24 0.71 .001 118 (75) 0.34 0.19 0.62 b .001
AR
(+ vs −) 118 (84) 0.48 0.30 0.75 .001 118 (75) 0.38 0.23 0.63 b .001
ERα
(+ vs −) 118 (84) 1.2 0.77 1.8 .4 118 (75) 1.1 0.69 1.7 .7
ERβ
(+ vs −) 117 (84) 1.2 0.62 2.2 .6 117 (75) 1.2 0.60 2.3 .6
Combined PR and AR expression
(PR+/AR+ vs PR− and/or AR−) 118 (84) 0.29 0.15 0.59 .001 118 (75) 0.21 0.092 0.49 b .001
Stage
(III-IV vs I-II) 118 (84) 4.4 2.3 8.3 b .001 118 (75) 4.0 2.0 7.8 b .001
Grade
Grade 1 vs grade 3 101 (69) 0.25 0.10 0.64 101 (64) 0.21 0.074 0.58
Grade 2 vs grade 3 101 (69) 0.99 0.57 1.7 101 (64) 0.81 0.45 1.4
Grade 3 101 (69) 1.0 .014 101 (64) 1.0 .010
Age at diagnosis
(b70 vs ≥70 years) 118 (84) 0.66 0.42 1.1 .083 118 (75) 0.43 0.27 0.70 .001
Histology
(Serous vs endometrioid) 118 (84) 1.7 1.0 2.9 .036 118 (75) 1.6 0.92 2.8 .094
BRCA mutation
(BRCA mutation vs wild type) 118 (84) 0.64 0.39 1.1 .092 118 (75) 0.59 0.33 1.0 .066
* P for grade on 2 degrees of freedom.
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retrospective study [32,35].
In the present study, no information on use of endocrine treatment
was available, precluding analyses of possible effects of endocrine
treatment on the findings reported. However, endocrine treatment is
not standard in ovarian cancer and is unlikely to have been administered
to the study cohort to such an extent that it has influenced the results
[14,19]. The present cohort is limited in size and therefore did not allow
thorough analyses in the separate histologic subgroups because of lack of
power. Nevertheless, stability analyses stratified for histology showed
that the effect of coexpression of PR and AR was present in both serous
and endometrioid tumors, thus justifying the combination of these two
histologies in the present study.Figure 2. Survival in relation to PR expression. (A) 5-Year PFS for PR
36.5%-69.1%) for PR-positive tumors compared with 18.3% (9.9%-26
5-year OS was 63.9% (48.2%-79.6%) for PR-positive tumors compare
calculated using the log-rank test.The link between endocrine receptor expression and prognosis may
relate to tumor differentiation, with reduced receptor levels being
reported in high-grade, aggressive tumors in both our study and others
[13,20]. This may at least partly explain why the presence of endocrine
receptors is prognostically favorable. BRCA1-associated breast cancers
in general lack expression of ER and PR, whereas BRCA2-dependent
breast cancers show more variability [36]. Likewise, the majority of
BRCA-associated ovarian tumors are high grade (and of serous
histology). A previous, small study did not find any differences in
expression of ERα, ERβ, PR, or AR between BRCA1-associated and
matched sporadic ovarian cancer cases, in line with our findings [37].
As has previously been shown, though, presence of a BRCA mutation
remained a strong predictor of outcome in this study [33,37].expression. The 5-year PFS was 52.8% ([95% confidence interval]
.7%) for PR-negative tumors. (B) 5-Year OS for PR expression. The
d with 24.4% (15.2%-33.6%) for PR-negative tumors. P values were
Figure 3. Survival in relation to AR expression. (A) 5-Year PFS for AR expression. The 5-year PFS was 44.2% ([95% confidence interval]
30.7%-57.7%) for AR-positive tumors compared with 16.7% (7.7%-25.7%) for AR-negative tumors. (B) 5-Year OS for AR expression. The
5-year OS was 57.7% (44.2%-71.2%) for AR-positive tumors compared with 19.7% (10.1%-29.3%) for AR-negative tumors. P values were
calculated using the log-rank test.
430 Sex Steroid Hormone Receptor and Ovarian Cancer Jönsson et al. Translational Oncology Vol. 8, No. 5, 2015Although increasing evidence supports a prognostic effect of PR
and AR expression in ovarian cancer, endocrine therapy has so far
only produced modest results with response rates of (at best) up to
18% for tamoxifen and 20%–40% for aromatase inhibitors [38–41].
Likewise, the effect of the antiprogesterone and antiglucocorticoid
agent mifepristone is questionable, as the initial encouraging results
have not been confirmed [42,43]. Promising effects have been
suggested in pilot studies of adjuvant treatment with medroxypro-
gesterone acetate plus platinum-containing chemotherapy in ad-
vanced ovarian cancer, with the best response among patients whose
tumors showed high expression of PR [44]. Confirmatory clinical
trials are however lacking. The above-mentioned results stand in
contrast to breast cancer, where expression of ER and PR predictsFigure 4. Survival in relation to combined PR and AR expression. (A) F
and AR expression. The 5-year PFS was 64.0% ([95% confidence in
(11.4%-27.4%) for tumors with dual negative or discordant receptor e
dual positive versus dual negative or discordant PR and AR expressio
compared with 25.8% (17.0%-34.6%) for tumors with dual negative or
log-rank test.response to endocrine treatment [6]. Of note, however, the response
to endocrine treatment may be related to the intrinsic molecular
subtypes in both tumor types.
The finding that aromatase inhibition appears slightly more
effective than tamoxifen in ovarian cancer likely reflects the more
efficient hormone inhibition of aromatase inhibitors. In support of
this notion, epidemiological studies indicate that reduced circulating
levels of androgens decrease the risk of developing ovarian cancer, but
clinical studies have shown only limited effects of androgen
deprivation [21,45,46]. At present, clinical efficacy data are lacking,
but the effect of endocrine treatment in ovarian cancer may be
underestimated because of the limited size of the studies performed to
date, inclusion of heavily pretreated patients, and a mixture ofive-year PFS for dual positive versus dual negative or discordant PR
terval] 45.2%-82.8%) for PR+/AR+ tumors compared with 19.4%
xpression (PR−/AR−, PR+/AR−, or PR−/AR+). (B) 5-Year OS for
n. The 5-year OS was 76.0% (59.3%-92.7%) for PR+/AR+ tumors
discordant receptor expression. P values were calculated using the
Table 3
5-Year PFS Multivariable Cox 5-Year OS Multivariable Cox
n (Events) HR 95% CI P n (Events) HR 95% CI P
Combined PR and AR expression
(PR+/AR+ vs PR− and/or AR−) 101 (69) 0.32 0.13 0.79 .014 101 (64) 0.24 0.080 0.70 .009
Stage
(III-IV vs I-II) 101 (69) 5.7 2.4 13.7 b .001 101 (64) 10.4 3.7 28.9 b .001
Grade
Grade 1 vs grade 3 101 (69) 0.53 0.18 1.6 101 (64) 0.58 0.17 2.0
Grade 2 vs grade 3 101 (69) 0.82 0.46 1.5 101 (64) 0.66 0.36 1.2
Grade 3 101 (69) 1.0 .5 101 (64) 1.0 .3
Age at diagnosis
(b70 vs ≥70 years) 101 (69) 0.90 0.54 1.5 .7 101 (64) 0.60 0.35 1.0 .059
BRCA mutation
(BRCA mutation vs wild type) 101 (69) 0.38 0.20 0.72 .003 101 (64) 0.34 0.17 0.67 .002
Histology
(Serous vs endometrioid) 101 (69) 0.57 0.28 1.2 .13 101 (64) 0.31 0.13 0.72 .007
* P for grade on 2 degrees of freedom.
Translational Oncology Vol. 8, No. 5, 2015 Sex Steroid Hormone Receptor and Ovarian Cancer Jönsson et al. 431different histologic types of ovarian cancer where receptor status was not
always assessed up front. The observation that AR expression decreases
following chemotherapy may also suggest that endocrine treatment
could be more effective in the adjuvant setting [21]. The presence and
prognostic value of AR expression in ovarian cancer vary in different
studies, but increased AR expression seems to generally be associated
with a favorable prognosis, as is also the case in the present study
[14,20,23]. In this study, the expression pattern for AR (44%AR+) and
PR (31%PR+) is in line with previous reports, whereas the frequency of
ERα positivity (44% ERα+) is lower [14,16,19,20]. In contrast, ERβ
positivity (82% ERβ+) was observed at a higher frequency [17].
Overall, the results vary somewhat between studies, which can probably
be explained by antibody specificity and the use of different cutoff levels,
not least for the less well-studied receptor ERβ [47]. For example, we
used an ERβ antibody binding to the functional, ligand binding
isoform, ERβ1. Taken together, this stresses the problem with less
studied markers, with lack of consensus on choice of antibody and
scoring. As presented in this study, double positivity for PR and AR
predicts both a better 5-year PFS and a better 5-year OS than either PR
or AR alone. The biological background for this is not clear, and to the
best of our knowledge, no functional interactions between PR and AR
have been described, but the most obvious common denominator is
ER(α). PR mediates the apoptotic and cell-differentiating effects of
progesterone on the ovaries and acts as a tumor suppressor, and estradiol
is also known to regulate the expression of PR. Thus, the function of the
receptors is probably of greater importance than the levels of receptor
expression [10]. In line with this, a recent study reported novel
functional interactions between PR and ERα, whereby progesterone
modulates ERα chromatin-binding events and transcriptional activity
in breast cancer cells [48]. One may therefore hypothesize that the
interaction described in this study may at least to some extent relate to
the genomic function of ERα, although this could not be captured in
the present analyses. Such a hypothesis is in line with the results from
previous studies, reporting an association between AR and ER(α)
expression in mixed ovarian cancer cohorts [20,23]. Likewise,
androstenedione constitutes a link between progesterone and testoster-
one, which may be linked to our finding of a positive predictive effect of
dual expression of PR and AR.
The various ovarian cancer subtypes have been suggested to signify
different disease entities, justifying separate assessment of the role of
endocrine factors in the molecular subtypes of ovarian cancer
[25,26,49]. Previous studies have investigated the differences in sexsteroid hormone receptor expression on both the protein and mRNA
levels in normal ovarian surface epithelium and ovarian cancer cells of
varying malignant potential and, although not completely consistent,
in general noted a decrease in receptor expression levels in malignant
compared with normal cells [17,50,51]. ERα, but not ERβ, protein
expression has also been shown to correlate well with corresponding
mRNA levels [17]. We investigated whether the prognostically
favorable effect seen in tumors expressing PR and AR, and especially in
those coexpressing both receptors, was paralleled by a similarly
favorable prognosis in tumors with high mRNA levels of the encoding
genes. We also hypothesized that the effect may vary in the different
molecular subtypes and therefore used an independent, publicly
available data set already stratified into subtypes to address this
question. As may be expected because of the great heterogeneity
among ovarian cancers, we could not establish any associations on the
mRNA level between ESR1, ESR2, PGR, or AR and PFS or OS in this
large independent data set of serous and endometrioid tumors. We
could however demonstrate a tendency toward different directions of
the associations between mRNA levels of PGR and ESR1 expression
and the immunoreactive and proliferative subtypes, but a clear
prognostic effect of dual high expression of PGR and AR was not
observed. This contrasts with the close relationship between, e.g., high
ER protein expression and high ESR1 gene expression and prognosis
seen in ER-positive breast cancer. It is therefore possible that the
regulation of sex steroid hormone receptor expression differs between
breast and ovarian cancer, but this study was not designed to address
that question. The intrinsic relationships and actions of sex steroid
hormone receptors may also be better captured by measurement of
modules of coregulated genes and/or microRNAs involved in
endocrine signaling. Based on the present findings, however, we
conclude that the variable effects of sex steroid hormone receptor gene
expression seen in the distinct molecular subtypes of ovarian cancer
support that intrinsic subtypes are considered also in future validation
studies and clinical treatment trials. Other factors involved in
endocrine signaling, in addition to the ones assessed in the present
study, may also reveal pertinent information regarding the true
prognostic value of sex steroid hormone receptors in ovarian cancer.
Conclusions
In conclusion, we demonstrate a prognostic role of PR and AR
expression in ovarian cancer, with independent effects on PFS and OS
and the best outcome for patients whose tumors displayed
Figure 5. Progression-free survival in relation to PGR and ARmRNA expression levels in the immunoreactive subtype. 3-Year PFS for dual
high versus dual low or discordant mRNA levels of PGR and AR in the immunoreactive subtype in an independent, publicly available data
set consisting of ovarian tumors (Tothill et al., Clin Cancer Res 2008*). The 3-year PFS was 47.6% ([95% confidence interval]
25.7%-88.2%) for tumors with dual high PGR and ARmRNA levels (high PGR/high AR) compared with 24.7% (13.5%-45.4%) for tumors
with dual low or discordant PGR and ARmRNA levels (low PGR/low AR, high PGR/low AR, or low PGR/high AR). The median mRNA value
across the samples was used as cutoff for high versus low expression. The P value was calculated using the log-rank test. Crosses
represent censored cases. *The data set consisted of 285 ovarian tumors, of which 251 were originally separated into 6 different
molecular subtypes. The 251 tumors with assigned subtypes were used in all gene expression analyses in this study.
432 Sex Steroid Hormone Receptor and Ovarian Cancer Jönsson et al. Translational Oncology Vol. 8, No. 5, 2015coexpression of PR and AR. We also reveal different expression levels
for the genes encoding ERα, ERβ, PR, and AR in the different
molecular subtypes of ovarian cancer in an independent data set, but
the relationship between mRNA levels and prognosis is uncertain.
Our data define a basis for further evaluation of the role of sex steroid
hormone receptors, and in the future possibly endocrine treatment, in
ovarian cancer and support that such studies may be subtype specific
to comprehensively evaluate the potential clinical benefit.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.09.002.
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